医学
荟萃分析
科克伦图书馆
肺动脉高压
安慰剂
随机对照试验
内科学
置信区间
不利影响
系统回顾
梅德林
病理
政治学
法学
替代医学
作者
Jinlv Qin,Guizuo Wang,Dong Han
标识
DOI:10.1016/j.cpcardiol.2022.101466
摘要
Despite the availability of treatments for all subgroups of pulmonary hypertension (PH), the prognosis for PH remains poor. This systematic review and meta-analysis aimed to determine the efficacy and safety of selexipag in patients with PH. A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of PH with selexipag, compared with placebo or blank, were reviewed. Studies were pooled to weighted mean differences (WMDs) and risk ratios (RRs), with 95% confidence intervals (CIs). Selexipag was safe and significantly improved hospitalization for worsening of PH, WHO FC, mPAP, NT-proBNP, and cardiac index in patients with PH. Selexipag should be considered in patients with pulmonary arterial hypertension or chronic thromboembolic PH.
科研通智能强力驱动
Strongly Powered by AbleSci AI